Показать сокращенную информацию
dc.contributor.author | Nomura S. | |
dc.contributor.author | Egawa Y. | |
dc.contributor.author | Urano S. | |
dc.contributor.author | Tahara T. | |
dc.contributor.author | Watanabe Y. | |
dc.contributor.author | Tanaka K. | |
dc.date.accessioned | 2021-02-25T20:56:18Z | |
dc.date.available | 2021-02-25T20:56:18Z | |
dc.date.issued | 2020 | |
dc.identifier.uri | https://dspace.kpfu.ru/xmlui/handle/net/162731 | |
dc.description.abstract | © 2020, The Author(s). In the field of molecular imaging, selectivity for target cells is a key determinant of the degree of imaging contrast. Previously, we developed a pre-targeted method by which target cells could be selectively imaged using a labeled N-glycan that was ligated in situ with an integrin-targeted cyclic RGD peptide on the cell surface. Here we demonstrate the power of our method in discriminating various cancerous and non-cancerous cells that cannot be distinguished using conventional RGD ligands. Using four cyclic RGDyK peptides with various linker lengths with five N-glycans, we identify optimal combinations to discriminate six types of αvβ3 integrin–expressing cells on 96-well plates. The optimal combinations of RGD and N-glycan ligands for the target cells are fingerprinted on the plates, and then used to selectively image tumors in xenografted mouse models. Using this method, various N-glycan molecules, even those with millimolar affinities for their cognate lectins, could be used for selective cancer cell differentiation. | |
dc.title | Cancer discrimination by on-cell N-glycan ligation | |
dc.type | Article | |
dc.relation.ispartofseries-issue | 1 | |
dc.relation.ispartofseries-volume | 3 | |
dc.collection | Публикации сотрудников КФУ | |
dc.source.id | SCOPUS-2020-3-1-SID85080035643 |